Hemex is the famous Corporate Investor, which was founded in 2011. The venture was found in Europe in Switzerland. The leading representative office of defined Corporate Investor is situated in the Liestal.
The current fund was established by Pascal Winnen, Paul Hadvu00e1ry.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Hemex, startups are often financed by Venture Kick, MassChallenge Switzerland, OCCIDENT. The meaningful sponsors for the fund in investment in the same round are OCCIDENT, Zu00fcrcher Kantonalbank ZKB, Zu00fcrcher Kantonal Bank. In the next rounds fund is usually obtained by Zu00fcrcher Kantonal Bank, TRUMPF Venture, OCCIDENT.
Besides, a startup needs to be aged 1 and less years to get the investment from the fund. Among the most popular fund investment industries, there are Medical, Biotechnology. Among the most popular portfolio startups of the fund, we may highlight Scailyte AG. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Switzerland.
The real fund results show that this Corporate Investor is 30 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2019. Deals in the range of 1 - 5 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually.
Related Funds
Funds with similar focus
Fund Name | Location |
23 High Networth Individuals (HNIs) | - |
Area Science Park | - |
Averill Master Fund | - |
Baixing.com | China, Shanghai |
BrokerTech Ventures | Des Moines, Iowa, United States |
Greybrook Realty Partners | Canada, Ontario, Toronto |
Gronova Vision | - |
Herald Investment Management | - |
MAS Angel Fund | Berlin, Berlin, Germany |
Scale Capital | Copenhagen, Denmark, Hovedstaden |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
hemotune | $15M | 25 Mar 2024 | Zurich, Zurich, Switzerland | ||
Aspivix | $5M | 17 Nov 2022 | Vaud, Switzerland | ||
hemotune | $7M | 26 Apr 2022 | Zurich, Zurich, Switzerland | ||
Scailyte | $654K | 12 Aug 2020 | Basel, Basel-City, Switzerland | ||
Scailyte | $3M | 09 Jun 2020 | Basel, Basel-City, Switzerland | ||
Annaida Technologies | $1M | 09 Apr 2020 | Lausanne, Vaud, Switzerland | ||
Resistell AG | $3M | 17 Dec 2019 | Basel, Basel-City, Switzerland | ||
Annaida Technologies | $152K | 07 Jun 2019 | Lausanne, Vaud, Switzerland | ||
Sleepiz | $1M | 29 May 2019 | Zurich, Switzerland |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
hemotune | $15M | 25 Mar 2024 | Zurich, Zurich, Switzerland | ||
Aspivix | $5M | 17 Nov 2022 | Vaud, Switzerland | ||
hemotune | $7M | 26 Apr 2022 | Zurich, Zurich, Switzerland | ||
Scailyte | $654K | 12 Aug 2020 | Basel, Basel-City, Switzerland | ||
Scailyte | $3M | 09 Jun 2020 | Basel, Basel-City, Switzerland | ||
Annaida Technologies | $1M | 09 Apr 2020 | Lausanne, Vaud, Switzerland | ||
Resistell AG | $3M | 17 Dec 2019 | Basel, Basel-City, Switzerland | ||
Annaida Technologies | $152K | 07 Jun 2019 | Lausanne, Vaud, Switzerland | ||
Sleepiz | $1M | 29 May 2019 | Zurich, Switzerland |